The USFDA issued six observations to Granules India’s Gagillapur facility in Hyderabad after an inspection between August 26 and September 6. The company is committed to addressing these issues promptly and will submit its response within the stipulated time frame. Following this news, Granules India’s stock fell by over 16% on the BSE.
Related Posts
A legacy has moved on, leaving behind his legacy
Ratan Tata’s legacy lives on through his impactful yet humble leadership. Known for his integrity and commitment, he turned challenges into triumphs, exemplified by his […]
Myntra joins Q-commerce rush with 30-minute deliveries
Myntra launches M-Now, a quick commerce service offering 30-minute deliveries of fashion and beauty products. Targeting young shoppers desiring instant gratification, M-Now leverages third-party dark […]